Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 23, 2026
Why Is IM Cannabis (IMCC) Stock Down -30.19% Today?

Why Is IM Cannabis (IMCC) Stock Down -30.19% Today?

Key Takeaways

  • Shares of IMCC plunged roughly 30% in Wednesday's session, falling from a prior close of $4.14 to about $2.89.
  • The primary catalyst was a deeply dilutive $1.31 million registered direct offering priced at $2.00 per share — a steep discount to the prior close.
  • The financing leaned on a "financial hardship" exemption, underscoring the company's serious liquidity strain and a going-concern warning flagged in recent quarters.
  • The drop also reflects a "buy the rumor, sell the news" unwind after a speculative rally tied to a planned pivot into defense technology.
  • Elevated volume and extreme intraday swings signal heavy retail-driven, momentum-style trading rather than a fundamental re-rating.

Opening Summary

IM Cannabis Corp. (IMCC), a medical cannabis operator with businesses in Israel and Germany, saw its shares sink sharply on Wednesday after the company priced a small but heavily dilutive stock offering well below the market. The stock closed the prior session at $4.14 and was trading around $2.89 by mid-afternoon, a decline of roughly 30.19%, or about $1.25 per share. The sell-off was driven by a combination of the discounted equity raise, renewed concerns about the company's balance sheet, and a pullback following days of speculative gains tied to its announced foray into the defense and unmanned aerial systems sector.

Dilutive Direct Offering Sparks the Sell-Off

The immediate trigger for Wednesday's decline was the pricing of a registered direct offering of 655,000 common shares at $2.00 per share, raising approximately $1.31 million in gross proceeds before expenses. Because the offering price represented a discount of more than 50% to the prior closing level, the deal carried a sharply dilutive signal for existing holders. The company said net proceeds would fund working capital and general corporate purposes, including the evaluation of additional business opportunities.

Critically, the financing was undertaken under a financial hardship exemption, a designation that requires a determination that the company is in serious financial difficulty. That framing reinforced investor concerns about IMCC's liquidity position, which had already been flagged through a going-concern warning and a series of small, high-cost convertible note raises in recent weeks. The market's reaction — a double-digit percentage decline on very heavy turnover — reflected the message that the company needs to raise capital at unfavorable terms.

Sell-the-News After the Defense Pivot Rally

The offering landed just as IMCC formally announced a non-binding letter of intent to acquire 51% of Space Defense Innovations LLC, a Polish entity operating in the tactical unmanned aerial systems market through its BlueAero Group subsidiary. The proposed pivot away from core cannabis operations had ignited a speculative frenzy earlier, with the stock surging dramatically on extremely heavy volume before pulling back.

Wednesday's action suggested a classic "sell the news" dynamic. With the defense deal now formalized — but still non-binding and subject to due diligence, definitive agreements, and regulatory approvals — traders who had chased the stock into its spike appeared to take profits, and the concurrent discounted offering gave them an additional reason to exit. The acquisition, while strategically notable, does not change the near-term financial picture, and the market refocused on execution risk and dilution.

Reverse Split and Nasdaq Compliance Backdrop

The volatility is occurring against a backdrop of corporate restructuring. IMCC completed a 1-for-30 reverse stock split in late August to support Nasdaq minimum bid price compliance, and it has disclosed plans to sell its European-focused assets while retaining its Israeli medical cannabis operations. These measures, combined with the going-concern disclosure, have kept the stock's beta and trading range elevated, leaving it prone to outsized moves in both directions on company-specific headlines.

Market Context and Trading Activity

Wednesday's decline was accompanied by unusually heavy trading activity, with millions of shares changing hands — far above the stock's typical daily turnover. The price action was highly volatile, with a wide intraday range that underscored the influence of short-term, momentum-oriented traders. The move was company-specific rather than a reflection of broad market weakness, as the cannabis and defense sectors showed no comparable systemic sell-off during the session.

Technically, the stock broke decisively below the prior session's close and slid through the psychologically significant $3.00 level, erasing a meaningful portion of the previous week's explosive rally. Despite the sharp drop, shares remain well above the 52-week low near $1.55, but they also trade far below the recent spike high reached during the initial defense-deal speculation.

What Comes Next for IMCC

Investors will be watching several developments closely. The direct offering is expected to close on or about September 24, and its completion will add to the share count while providing limited near-term relief. The proposed Space Defense Innovations transaction remains contingent on due diligence and the negotiation of definitive agreements, with no assurance of closing. The company's next earnings report is anticipated in November, when management's commentary on liquidity, the status of the European asset sale, and any progress on the defense pivot will be closely scrutinized.

Key risks include continued dilution from future financings, the possibility that the defense acquisition does not close, ongoing Nasdaq listing compliance concerns, and the company's persistent operating losses. Given the elevated volatility and the stock's thin, retail-heavy shareholder base, further sharp swings are likely in both directions.

Trending AI Robots

For traders seeking a more systematic approach to fast-moving markets, Tickeron's Trending AI Robots page offers a curated selection of AI-driven trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore a range of data-driven approaches. Consider reviewing the Trending AI Robots to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IMCC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for IMCC turns negative, indicating new downward trend

IMCC saw its Momentum Indicator move below the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 82 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for IMCC crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

IMCC broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMCC entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for IMCC just turned positive on September 25, 2026. Looking at past instances where IMCC's MACD turned positive, the stock continued to rise in 31 of 37 cases over the following month. The odds of a continued upward trend are 84%.

Following a +159.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in 166 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.949) is normal, around the industry mean (43.873). P/E Ratio (0.000) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.13B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -5%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 13%. PCRX experienced the highest price growth at 47%, while SXTC experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -18%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 56
SMR Rating: 86
Profit Risk Rating: 84
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
IMCC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
Central District
Phone
+972 773603504
Employees
44
Web
https://www.imcannabis.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.